Loading...
•
Dec 31, 2025
Aurinia Q4 2025 Earnings Report
Aurinia Q4 2025 Earnings Report
Key Takeaways
Aurinia delivered a strong fourth quarter with total revenue growing 29% year-over-year, driven primarily by increased LUPKYNIS sales. The company reported a significant net income boost due to a one-time $175.1 million income tax benefit from the release of valuation allowances on deferred tax assets.
Q4 total revenue reached $77.1 million, a 29% increase compared to the same period in 2024.
Net income for the quarter was $210.8 million, largely impacted by a $175.1 million non-cash income tax benefit.
Cash flow from operating activities for Q4 improved to $45.7 million, up 52% year-over-year.
The company repurchased 12.2 million common shares during the full year 2025 for a total of $98.2 million.
Revenue by Segment
Forward Guidance
Aurinia provided full-year 2026 guidance reflecting continued growth in LUPKYNIS sales and total revenue.
Positive Outlook
- 2026 total revenue expected between $315 million and $325 million.
- 2026 net product sales expected between $305 million and $315 million.
- Anticipated 11% to 15% growth in total revenue compared to 2025.
- Planned initiation of a clinical study for aritinercept in a second autoimmune disease in H1 2026.
- Focus on increasing LUPKYNIS adoption among lupus nephritis patients.
Challenges Ahead
- License and royalty revenue for the full year 2025 decreased 38% compared to 2024 due to a prior year milestone.
- Research and development expenses increased significantly in Q4 compared to the prior year.
- The company faces substantial risks and uncertainties regarding the timing of clinical study results.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...